226 related articles for article (PubMed ID: 19633417)
1. Mutant p53 rescue and modulation of p53 redox state.
Bykov VJ; Lambert JM; Hainaut P; Wiman KG
Cell Cycle; 2009 Aug; 8(16):2509-17. PubMed ID: 19633417
[TBL] [Abstract][Full Text] [Related]
2. p53 as a hub in cellular redox regulation and therapeutic target in cancer.
Eriksson SE; Ceder S; Bykov VJN; Wiman KG
J Mol Cell Biol; 2019 Apr; 11(4):330-341. PubMed ID: 30892598
[TBL] [Abstract][Full Text] [Related]
3. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.
Lambert JM; Gorzov P; Veprintsev DB; Söderqvist M; Segerbäck D; Bergman J; Fersht AR; Hainaut P; Wiman KG; Bykov VJ
Cancer Cell; 2009 May; 15(5):376-88. PubMed ID: 19411067
[TBL] [Abstract][Full Text] [Related]
4. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
[TBL] [Abstract][Full Text] [Related]
5. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
Wiman KG
Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
[TBL] [Abstract][Full Text] [Related]
6. Restoring p53-dependent tumor suppression.
Wang W; Rastinejad F; El-Deiry WS
Cancer Biol Ther; 2003; 2(4 Suppl 1):S55-63. PubMed ID: 14508081
[TBL] [Abstract][Full Text] [Related]
7. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.
Farnebo M; Bykov VJ; Wiman KG
Biochem Biophys Res Commun; 2010 May; 396(1):85-9. PubMed ID: 20494116
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
Wiman KG
Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 reactivation by small molecules makes its way to the clinic.
Bykov VJ; Wiman KG
FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
[TBL] [Abstract][Full Text] [Related]
10. p53: a guide to apoptosis.
Meulmeester E; Jochemsen AG
Curr Cancer Drug Targets; 2008 Mar; 8(2):87-97. PubMed ID: 18336191
[TBL] [Abstract][Full Text] [Related]
11. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
Bossi G; Sacchi A
Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
Garufi A; Pistritto G; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
[TBL] [Abstract][Full Text] [Related]
13. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
14. Identification of GRO1 as a critical determinant for mutant p53 gain of function.
Yan W; Chen X
J Biol Chem; 2009 May; 284(18):12178-87. PubMed ID: 19258312
[TBL] [Abstract][Full Text] [Related]
15. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.
Puca R; Nardinocchi L; Givol D; D'Orazi G
Oncogene; 2010 Aug; 29(31):4378-87. PubMed ID: 20514025
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in p53 research and cancer treatment.
Suzuki K; Matsubara H
J Biomed Biotechnol; 2011; 2011():978312. PubMed ID: 21765642
[TBL] [Abstract][Full Text] [Related]
17. Prospects for p53-based cancer therapy.
Stokłosa T; Gołab J
Acta Biochim Pol; 2005; 52(2):321-8. PubMed ID: 15990917
[TBL] [Abstract][Full Text] [Related]
18. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
Baptiste N; Friedlander P; Chen X; Prives C
Oncogene; 2002 Jan; 21(1):9-21. PubMed ID: 11791172
[TBL] [Abstract][Full Text] [Related]
19. Restoration of p53 to limit tumor growth.
Wang W; El-Deiry WS
Curr Opin Oncol; 2008 Jan; 20(1):90-6. PubMed ID: 18043262
[TBL] [Abstract][Full Text] [Related]
20. Novel cancer therapy by reactivation of the p53 apoptosis pathway.
Bykov VJ; Wiman KG
Ann Med; 2003; 35(7):458-65. PubMed ID: 14649328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
